Life Sciences Business in India- Real Stories from Ground Zero
Life Sciences business in India is the next wave. in fact, it is the current one. Much has been said about why India is the ideal destination for drug development, manufacturing, clinical trials, contract services. and almost everything else. So it seems intuitive that entrepreneurs with an India focus would find it easy to capitalize on all that India has to offer.
The question of course is. is that true? The answers come from our panel- a group of individuals who are living this question, trying to raise money, develop proprietary drugs, provide contract services, and facilitate the formation and funding of Life Science entities in India. Please join us to learn what life is really like for the India-centric Life Sciences entrepreneur.
Place: Crowne Palace Cabana, 4290 El Camino Real, Palo Alto, CA 94306
Date: November 15, 2006
Networking/Dinner: 6:30 pm
Panel discussion: 7:30 pm
End: 8:00 pm
Members: $15 (pre-registration), $20 (on-site)
Non-members: $20 (pre-registration), $25 (on-site)
Anula Jayasuriya, MD, PhD, MBA
Anula Jayasuriya, a life science venture capitalist, is the co-founder of a new Investment Fund, “Evolvence India Life Sciences”, investing in India-centric opportunities. She is currently in the process of raising the fund and has been interacting extensively with potential investors for Life Science opportunities in India.
Anula’s expertise consists of a unique combination of business, basic science and medical knowledge. She was also a partner with Skyline Ventures in Palo Alto, and prior to that with the German – US venture capital firm TVM, in San Francisco. Her prior positions include VP-Corporate development at Genomics Collaborative Inc., and Vice President, Global Drug Development at Hoffman-La Roche for opportunistic infections in AIDS and Transplantation.
Anula received a BA from Harvard summa cum laude, and an MD and PhD (in Microbiology and Molecular Genetics) from Harvard Medical School. She interned in Pediatrics at Boston Children’s Hospital and received an MBA with distinction from Harvard Business School. Anula also has a M. Phil. in pharmacology from the University of Cambridge, England.
Fred Greguras, JD
Fred is an attorney in the Corporate Group of Fenwick & West, LLP, a multinational law firm very involved in the Life Sciences business in Asia. He has represented many India-centric startups in the software/outsourcing space and is now doing the same for companies in the Life Sciences space.
Fred focuses on strategic legal issues for software, semiconductor-related and life sciences companies. His practice includes start-up issues and financings in both domestic and international transactions. He has represented a wide range of companies in financing, M&A, licensing and other commercial transactions, from privately held start-ups to publicly traded companies. He has also been a venture capitalist and a general counsel and CFO for an India outsourcing startup. He has authored many articles on start-up financing, outsourcing, Internet and international legal issues.
Fred received his J.D. from the University of Nebraska in 1975 and M.S., in mathematics and computer science from the University of Nebraska in1968.
Rajnish Mishra, PhD
Rajnish is CEO of Avaan Therapeutics- a startup focused on developing new drugs in India for worldwide markets. Avaan is currently in the process of acquiring molecules to implement its drug development paradigm.
Rajnish is an accomplished entrepreneur and business executive. He started his first venture, Quantros, while in graduate school. During his tenure as President & CEO, the company delivered triple-digit growth rates in revenues, and acquired a top competitor. Rajnish took the company from concept to profitability in less than 4 years. Quantros is now a leading provider of patient safety, regulatory reporting and outcomes research solutions to the Healthcare Industry. Rajnish’s passion for startups is evident from his second venture, Avaan Therapeutics. Avaan has assembled a seasoned drug development team – former Pfizer executives and researchers with a proven track record of molecule selection and execution.
Rajnish has a PhD in Pharmaceutical Administration and MBA from University of Louisiana. He is a computer engineer from University of Bombay. He currently serves on Quantros’ Board of Directors.
Jhansi Reddy is the CEO of Maya Clinicals, a clinical research organization based in the San Francisco bay area with offices and infrastructure in the US, Europe and India. Maya intends to pool all its resources globally to accelerate drug development. The company is currently soliciting clients in the US for clinical work to be done in India.
Jhansi previously worked as a manager at MedImmune Vaccines and has played an important role in the testing, development, validation, automation, compliance and clinical areas for the FluMist vaccine development and release. She has also worked at University of Utah Medical Center and Stanford University Medical Center in basic research in Pathology, Infectious Diseases, Nuclear Medicine, and Anesthesiology. Also she has managed Quality and development at Empyrean Diagnostics in Mountain View making HIV diagnostic kits and did consulting for Alza, Dendreon, Cholestech, Metra Biosystems in manufacturing, quality and development.
She has unique background managing all the aspects of drug development in both academia and industry and has a thorough understanding of the processes. She has a B.Sc in Biology from Andhra University, A.P, India and a M.S from University of Utah, Salt Lake City in Biology.
Anish Bhatnagar, MD